Anal Cancer-Pipeline Review, H1 2016

Anal Cancer-Pipeline Review, H1 2016


  • Products Id :- GMDHC7766IDB
  • |
  • Pages: 86
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Anal Cancer-Pipeline Review, H1 2016', provides an overview of the Anal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Anal Cancer

The report reviews pipeline therapeutics for Anal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Anal Cancer therapeutics and enlists all their major and minor projects

The report assesses Anal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Anal Cancer

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Anal Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Anal Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Anal Cancer Overview 7

Therapeutics Development 8

Pipeline Products for Anal Cancer-Overview 8

Pipeline Products for Anal Cancer-Comparative Analysis 9

Anal Cancer-Therapeutics under Development by Companies 10

Anal Cancer-Therapeutics under Investigation by Universities/Institutes 12

Anal Cancer-Pipeline Products Glance 13

Clinical Stage Products 13

Early Stage Products 14

Anal Cancer-Products under Development by Companies 15

Anal Cancer-Products under Investigation by Universities/Institutes 16

Anal Cancer-Companies Involved in Therapeutics Development 17

Advaxis, Inc. 17

Amgen Inc. 18

Eli Lilly and Company 19

Genticel S.A. 20

ISA Pharmaceuticals B.V. 21

Novartis AG 22

Oryx GmbH & Co. KG 23

PDS Biotechnology Corporation 24

Sun Pharma Advanced Research Company Ltd. 25

Taiwan Liposome Company, Ltd. 26

Anal Cancer-Therapeutics Assessment 27

Assessment by Monotherapy Products 27

Assessment by Target 28

Assessment by Mechanism of Action 30

Assessment by Route of Administration 32

Assessment by Molecule Type 34

Drug Profiles 36

axalimogene filolisbac-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Cellular Immunotherapy for HPV Associated Cancers-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

GTL-001-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

ISA-101-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

LN-145-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

paclitaxel albumin free-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

panitumumab-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

PDR-001-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

PDS-0101A-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

prexasertib-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

TLC-388-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Vicoryx-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Anal Cancer-Recent Pipeline Updates 57

Anal Cancer-Dormant Projects 77

Anal Cancer-Product Development Milestones 78

Featured News & Press Releases 78

Dec 16, 2015: FDA Lifts Advaxis Clinical Hold On Axalimogene Filolisbac 78

Dec 14, 2015: Advaxis Receives Orphan Drug Designation in the European Union for Axalimogene Filolisbac for the Treatment of Anal Cancer 78

Nov 02, 2015: Advaxis Provides Additional Information on Clinical Hold 78

Apr 06, 2015: Advaxis and RTOG Foundation to Collaborate on Pivotal Phase 2/3 Clinical Trial of ADXS-HPV in Anal Cancer 79

Oct 15, 2014: Advaxis Provides Clinical Update for Phase 1/2 Trial of ADXS-HPV Immunotherapy Product Candidate in Anal Cancer 80

Feb 11, 2014: SynCo Bio Partners Expands Live Microbial Product Experience 80

Jun 24, 2013: Advaxis Requests Orphan Drug Designation For Treatment Of HPV-Associated Anal Cancer with ADXS-HPV 81

Apr 22, 2013: Advaxis Announces First Patient Dosed In Brown University Sponsored Phase I/II Anal Cancer Study Of ADXS-HPV 81

Mar 03, 2013: Advaxis Provides Update On ADXS-HPV Cancer Immunotherapy 82

Feb 19, 2013: Advaxis Announces Brown University Oncology Group To Conduct Phase I/II Trial Of ADXS-HPV In Anal Cancer 83

Appendix 85

Methodology 85

Coverage 85

Secondary Research 85

Primary Research 85

Expert Panel Validation 85

Contact Us 85

Disclaimer 86

List of Figures

Number of Products under Development for Anal Cancer, H1 2016 8

Number of Products under Development for Anal Cancer-Comparative Analysis, H1 2016 9

Number of Products under Development by Companies, H1 2016 10

Comparative Analysis by Clinical Stage Development, H1 2016 13

Assessment by Monotherapy Products, H1 2016 27

Number of Products by Targets, H1 2016 28

Number of Products by Stage and Targets, H1 2016 28

Number of Products by Mechanism of Actions, H1 2016 30

Number of Products by Stage and Mechanism of Actions, H1 2016 30

Number of Products by Routes of Administration, H1 2016 32

Number of Products by Stage and Routes of Administration, H1 2016 32

Number of Products by Molecule Types, H1 2016 34

Number of Products by Stage and Molecule Types, H1 2016 34

List of Tables

Number of Products under Development for Anal Cancer, H1 2016 8

Number of Products under Development for Anal Cancer-Comparative Analysis, H1 2016 9

Number of Products under Development by Companies, H1 2016 11

Number of Products under Investigation by Universities/Institutes, H1 2016 12

Comparative Analysis by Clinical Stage Development, H1 2016 13

Comparative Analysis by Early Stage Development, H1 2016 14

Products under Development by Companies, H1 2016 15

Products under Investigation by Universities/Institutes, H1 2016 16

Anal Cancer-Pipeline by Advaxis, Inc., H1 2016 17

Anal Cancer-Pipeline by Amgen Inc., H1 2016 18

Anal Cancer-Pipeline by Eli Lilly and Company, H1 2016 19

Anal Cancer-Pipeline by Genticel S.A., H1 2016 20

Anal Cancer-Pipeline by ISA Pharmaceuticals B.V., H1 2016 21

Anal Cancer-Pipeline by Novartis AG, H1 2016 22

Anal Cancer-Pipeline by Oryx GmbH & Co. KG, H1 2016 23

Anal Cancer-Pipeline by PDS Biotechnology Corporation, H1 2016 24

Anal Cancer-Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016 25

Anal Cancer-Pipeline by Taiwan Liposome Company, Ltd., H1 2016 26

Assessment by Monotherapy Products, H1 2016 27

Number of Products by Stage and Target, H1 2016 29

Number of Products by Stage and Mechanism of Action, H1 2016 31

Number of Products by Stage and Route of Administration, H1 2016 33

Number of Products by Stage and Molecule Type, H1 2016 35

Anal Cancer Therapeutics-Recent Pipeline Updates, H1 2016 57

Anal Cancer-Dormant Projects, H1 2016 77

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Advaxis, Inc.

Amgen Inc.

Eli Lilly and Company

Genticel S.A.

ISA Pharmaceuticals B.V.

Novartis AG

Oryx GmbH & Co. KG

PDS Biotechnology Corporation

Sun Pharma Advanced Research Company Ltd.

Taiwan Liposome Company, Ltd.

Anal Cancer Therapeutic Products under Development, Key Players in Anal Cancer Therapeutics, Anal Cancer Pipeline Overview, Anal Cancer Pipeline, Anal Cancer Pipeline Assessment

select a license

Single User License
USD 2000 INR 128520
Site License
USD 4000 INR 257040
Corporate User License
USD 6000 INR 385560

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com